Mural Oncology to Present at Two Upcoming Investor Conferences
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced its participation in two upcoming investor conferences. The company, which develops novel engineered cytokine therapies for cancer patients, will be represented by key management team members at these events:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 at 1:50 p.m. ET, featuring a fireside chat with CEO Caroline Loew, Ph.D., Chief Medical Officer Vicki Goodman, MD, and CFO Adam Cutler.
2. H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 9:30 a.m. ET, where CEO Caroline Loew, Ph.D. will give a presentation.
Webcasts of both presentations will be available on the company's investor relations website. The management team will also be available for one-on-one meetings during these conferences.
Mural Oncology plc (Nasdaq: MURA), un'azienda di immuno-oncologia in fase clinica, ha annunciato la sua partecipazione a due importanti conferenze per investitori. L'azienda, che sviluppa nuove terapie con citochine ingegnerizzate per i pazienti affetti da cancro, sarà rappresentata da membri chiave del team dirigenziale in questi eventi:
1. 22° Conferenza Annuale Globale sulla Salute di Morgan Stanley il 6 settembre alle 13:50 ET, con una chiacchierata informale con il CEO Caroline Loew, Ph.D., il Chief Medical Officer Vicki Goodman, MD, e il CFO Adam Cutler.
2. 26° Conferenza Annuale Globale sugli Investimenti di H.C. Wainwright l'11 settembre alle 9:30 ET, dove il CEO Caroline Loew, Ph.D. terrà una presentazione.
I webcast di entrambe le presentazioni saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda. Inoltre, il team dirigenziale sarà disponibile per incontri uno-a-uno durante queste conferenze.
Mural Oncology plc (Nasdaq: MURA), una empresa de inmuno-oncología en etapa clínica, ha anunciado su participación en dos próximas conferencias para inversores. La empresa, que desarrolla nuevas terapias de citoquinas diseñadas para pacientes con cáncer, estará representada por miembros clave del equipo directivo en estos eventos:
1. 22ª Conferencia Anual Global de Salud de Morgan Stanley el 6 de septiembre a la 1:50 p.m. ET, que contará con una charla informal con la CEO Caroline Loew, Ph.D., la Directora Médica Vicki Goodman, MD, y el CFO Adam Cutler.
2. 26ª Conferencia Anual Global de Inversión de H.C. Wainwright el 11 de septiembre a las 9:30 a.m. ET, donde la CEO Caroline Loew, Ph.D. dará una presentación.
Los webcasts de ambas presentaciones estarán disponibles en el sitio web de relaciones con los inversores de la empresa. El equipo directivo también estará disponible para reuniones uno a uno durante estas conferencias.
Mural Oncology plc (Nasdaq: MURA)는 임상 단계의 면역 종양학 회사로, 두 개의 예정된 투자자 회의에 참석할 것이라고 발표했습니다. 암 환자를 위한 새로운 엔지니어링 사이토카인 요법을 개발하는 이 회사는 다음 이벤트에서 주요 관리 팀 멤버들이 대표로 참석합니다:
1. 모건 스탠리 제22회 연례 글로벌 건강 회의가 9월 6일 오후 1시 50분 ET에 열리며, CEO 캐롤린 로우 박사, 수석 의료 담당자 비키 굿맨 박사, CFO 아담 커틀러와의 비공식 대화가 진행됩니다.
2. H.C. 웨인라이트 제26회 연례 글로벌 투자 회의가 9월 11일 오전 9시 30분 ET에 열리며, CEO 캐롤린 로우 박사가 발표를 진행합니다.
두 발표의 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공될 것입니다. 관리 팀은 이 회의 중 일대일 미팅을 위해서도 참석할 예정입니다.
Mural Oncology plc (Nasdaq: MURA), une entreprise d'immuno-oncologie en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise, qui développe de nouvelles thérapies à base de cytokines ingénieries pour les patients atteints de cancer, sera représentée par des membres clés de son équipe de direction lors de ces événements :
1. 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 6 septembre à 13h50 ET, avec une discussion informelle avec le PDG Caroline Loew, Ph.D., le directeur médical Vicki Goodman, MD, et le CFO Adam Cutler.
2. 26ème Conférence Annuelle Mondiale sur les Investissements de H.C. Wainwright le 11 septembre à 9h30 ET, où le PDG Caroline Loew, Ph.D. fera une présentation.
Les webcasts des deux présentations seront disponibles sur le site web des relations avec les investisseurs de l'entreprise. De plus, l'équipe de direction sera disponible pour des réunions individuelles lors de ces conférences.
Mural Oncology plc (Nasdaq: MURA), ein Unternehmen für immunonkologische Therapien in klinischer Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen, das neuartige ingenieurtechnisch entwickelte Zytokinterapien für Krebspatienten entwickelt, wird bei diesen Veranstaltungen von wichtigen Mitgliedern des Managementteams vertreten:
1. 22. Jährliche Globale Gesundheitskonferenz von Morgan Stanley am 6. September um 13:50 Uhr ET, bei der ein informelles Gespräch mit CEO Caroline Loew, Ph.D., Chief Medical Officer Vicki Goodman, MD, und CFO Adam Cutler stattfinden wird.
2. 26. Jährliche Globale Investorenkonferenz von H.C. Wainwright am 11. September um 9:30 Uhr ET, bei der CEO Caroline Loew, Ph.D. eine Präsentation halten wird.
Die Webcasts beider Präsentationen werden auf der Investor-Relations-Website des Unternehmens verfügbar sein. Das Managementteam wird während dieser Konferenzen auch für persönliche Gespräche zur Verfügung stehen.
- None.
- None.
WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of its management team will participate at two upcoming investor conferences and take 1x1 meetings. A webcast of both presentations will be available at ir.muraloncology.com.
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside chat with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Medical Officer, and Adam Cutler, Chief Financial Officer
Date: Friday, September 6
Time: 1:50 p.m. ET
H.C. Wainwright 26th Annual Global Investment Conference
Presentation by Caroline Loew, Ph.D.
Date: Wednesday, September 11
Time: 9:30 a.m. ET
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Contact
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
What investor conferences will Mural Oncology (MURA) attend in September 2024?
Who will represent Mural Oncology (MURA) at the Morgan Stanley healthcare conference?
When is Mural Oncology's (MURA) presentation at the H.C. Wainwright conference?
Where can investors watch the webcasts of Mural Oncology's (MURA) conference presentations?
